Population pharmacokinetics of dolutegravir in HIV-infected treatment-naive patients

AIM: Dolutegravir is the newest integrase inhibitor approved for HIV treatment and has demonstrated potent antiviral activity in patient populations with a broad range of treatment experience. This analysis aimed to characterize the population pharmacokinetics of dolutegravir in treatment-naive pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Jianping, Hayes, Siobhán, Sadler, Brian M, Minto, Ilisse, Brandt, Julie, Piscitelli, Steve, Min, Sherene, Song, Ivy H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2015
Materias:
Clinical Trials
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4574835/
https://www.ncbi.nlm.nih.gov/pubmed/25819132
http://dx.doi.org/10.1111/bcp.12639

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4574835/
https://www.ncbi.nlm.nih.gov/pubmed/25819132
http://dx.doi.org/10.1111/bcp.12639

Ejemplares similares